BTIG Reiterates Buy Rating on vTv Therapeutics (VTVT): "Street overlooking small molecule portfolio"

March 11, 2026 11:09 AM

BTIG analyst Kambiz Yazdi reiterated a Buy rating and $49.00 price target on vTv Therapeutics (NASDAQ: VTVT)The analyst commented, "vTv ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found